Home in
 

Keywords :   


Tag: in

Statoil submits plan for development and operation for Utgard field in North Sea

2016-08-10 01:00:00| Offshore Technology

Statoil and its partners have submitted the plan for development and operation (PDO) and the field development plan (FDP) to Norwegian and UK authorities for its Utgard field in the North Sea.

Tags: in plan development north

 

Statoil submits plan for development and operation for Utgard field in North Sea

2016-08-10 01:00:00| Offshore Technology

Statoil and its partners have submitted the plan for development and operation (PDO) and the field development plan (FDP) to Norwegian and the UK authorities for its Utgard field in the North Sea.

Tags: in plan development north

 
 

CIDESCO Makeup & Body Art Competition is Sept. 26 in Dublin

2016-08-09 10:00:00| Happi Breaking News

"Myths & Legends of the World Unite" is this year's theme.

Tags: in art body competition

 

Wintershall Norge gets drilling permit for well 35/11-20 B in North Sea

2016-08-09 01:00:00| Offshore Technology

Wintershall Norge has secured a drilling permit from the Norwegian Petroleum Directorate for well 35/11-20 B in North Sea.

Tags: in north sea permit

 

Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

2016-08-08 23:05:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in of results study

 

Sites : [444] [445] [446] [447] [448] [449] [450] [451] [452] [453] [454] [455] [456] [457] [458] [459] [460] [461] [462] [463] next »